Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Freeline Therapeutics

Freeline Therapeutics
2015 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$118M LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of a bio-pharmaceutical platform intended to create better lives for people suffering from chronic, debilitating disease. The company has developed a next-generation AAV based gene therapy with focused on the development and commercialization by providing a long-lasting, safe and reliable source of enzymes, enabling physicians to treat patients with chronic diseases.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Primary Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road
  • Stevenage SG1 2FX
  • England, United Kingdom

+44 020 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Freeline Therapeutics’s full profile, request a free trial.

Freeline Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 19-Jun-2018 $118M 00000 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 10-May-2018 000.00 000.00 0000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Freeline Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00
To view this company’s complete Cap Table, request access »

Freeline Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Albion Capital Venture Capital Minority 000 0000 000000 0
Syncona Venture Capital Minority 000 0000 000000 0
University College London University Minority 000 0000 000000 0

Freeline Therapeutics Executive Team (11)

Name Title Board
Seat
Contact
Info
Brian Silver JD Chief Financial Officer & Head of Corporate Development
Markus Horer Ph.D Co-Founder, Chief Technology Officer & Managing Director
Jan Thirkettle Ph.D Chief Development Officer
Amit Nathwani Co-Founder, Chief Scientific Officer & Board Member
Karen Law Executive

2 Former Executives

You’re viewing 5 of 11 executives. Get the full list »

Freeline Therapeutics Board Members (5)

Name Representing Role Since Contact
Info
Amit Nathwani Freeline Therapeutics Co-Founder, Chief Scientific Officer & Board Member 000 0000
Christopher Hollowood Ph.D Syncona Executive Chairman 000 0000
Martin Andrews Freeline Therapeutics Board Member 000 0000

2 Former Board Members

You’re viewing 3 of 5 board members. Get the full list »